Korean-Japanese Billionaire Masayoshi Son’s 2022 Portfolio: 5 Stocks to Watch

Page 5 of 5

1. EQRx, Inc. (NASDAQ:EQRX)

SB Management’s Stake Value: $178.31 million

Percentage of SB Management’s 13F Portfolio: 34.56%

Number of Hedge Fund Holders: 31

EQRx, Inc. (NASDAQ:EQRX) is a Massachusetts-based pharmaceutical firm which develops drugs for a range of oncology and immune-inflammatory diseases. It also seeks to provide patients with access to life-saving drugs at discounted, affordable prices.

On April 22, Cowen analyst Steve Scala initiated coverage of EQRx, Inc. (NASDAQ:EQRX) with an ‘Outperform’ rating without a price target. The analyst notes that the firm has late-stage assets in “high growth areas” and innovation partners to develop more, and is also working to create a new model in which drugs are sold at highly discounted prices through a network of buyers. He sees the company shares presenting an attractive investment opportunity.

Out of all the hedge funds tracked by Insider Monkey, 31 held positions in EQRx, Inc. (NASDAQ:EQRX) with a combined value of $775.6 million.

You can also take a look at Billionaire Andreas Halvorsen’s Top Stock Picks and 10 Best Mid-Cap Stocks To Buy Now.

Page 5 of 5